What's Happening?
The U.S. Department of Labor’s (DOL) Employee Benefits Security Administration (EBSA) has released a final rule that mandates new disclosure requirements for pharmacy benefit management (PBM) services provided to large, self-insured group health plans
under the Employee Retirement Income Security Act (ERISA). This rule, applicable to plan years beginning on or after July 1, 2027, aims to increase transparency into PBM compensation and financial arrangements. It requires PBMs to provide detailed written information about expected compensation before entering, extending, or renewing contracts, including direct fees, manufacturer rebates, spread compensation, and drug-pricing methodologies. The rule also grants covered plans significant audit rights, allowing them to verify the accuracy of disclosures at least once a year. This initiative follows amendments to ERISA enacted in the Consolidated Appropriations Act, 2026 (CAA 2026), which clarified PBMs as covered service providers.
Why It's Important?
This final rule is a significant development for self-insured ERISA plans, particularly those with at least 100 employees, as it empowers plan fiduciaries with greater visibility into the often-opaque financial dealings of PBMs. By requiring detailed disclosures and audit rights, the DOL seeks to ensure that PBM contracts and compensation are reasonable, thereby protecting plan participants and beneficiaries. This increased transparency could lead to more competitive PBM contracts, potentially lowering healthcare costs for employers and employees. Conversely, PBMs and other covered service providers will need to adapt to substantially greater scrutiny of their financial arrangements, which may necessitate changes in their operational and contractual practices. The rule underscores the DOL's commitment to overseeing the complex PBM industry and ensuring fair practices within the healthcare benefits landscape.
What's Next?
The final rule is effective 60 days after its publication in the Federal Register and will apply to plan years beginning on or after July 1, 2027. PBMs and covered service providers must prepare for these new requirements, including providing semiannual disclosures of compensation received and allowing plan-selected auditors to verify information. The DOL has adopted a temporary enforcement policy for the period from February 3, 2026, through the rule’s applicability date, during which good-faith interpretations of the amended ERISA provisions will be considered. Plan sponsors and fiduciaries should review their existing PBM contracts, renewal procedures, and data-access provisions to ensure compliance with the new regulations and leverage their enhanced audit rights.
Beyond the Headlines
The DOL's final rule reflects a growing regulatory focus on the pharmaceutical supply chain and the role of PBMs in healthcare costs. The increased transparency could expose practices that contribute to rising drug prices, potentially leading to broader reforms in how medications are priced and distributed. This move also highlights the ongoing tension between the need for proprietary business practices and the public interest in affordable healthcare. The emphasis on fiduciary responsibility under ERISA means that plan sponsors will bear a greater burden in scrutinizing PBM arrangements, potentially leading to more litigation if disclosures are found to be inadequate or if PBMs fail to act in the best interest of the plans. This rule could set a precedent for similar transparency requirements in other sectors of the healthcare industry.
